Key result
Long-term antipsychotic use chlorpromazine equivalents were listed in a supplementary table without reporting clinical outcomes.
Why the study?
Does long-term antipsychotic use improve outcomes in schizophrenia subjects?
Population
53 schizophrenia subjects from the Northern Finland Birth Cohort 1966 with at least ten years of follow-up
Design
Cohort
Follow-up
at least 10 years (mean 18.6 years since illness onset)
Authors
Loading...
Limits interpretation of dosing effects; leaves open long-term antipsychotic benefits in schizophrenia.
Cohort
Does long-term antipsychotic use improve outcomes in schizophrenia subjects?
In a population-based cohort of schizophrenia patients, low dose and proportion of antipsychotic use, as well as having no drug-free periods, are associated with better long-term outcomes.
Moilanen et al. (2016) conducted a cohort in schizophrenia. Long-term antipsychotic use was evaluated. Long-term antipsychotic use chlorpromazine equivalents were listed in a supplementary table without reporting clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: